Catalyst
Slingshot members are tracking this event:
Cidara Therapeutics plans to initiate a Phase 2 trial for CD101 IV in treating candidemia in the first half of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CDTX | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 09, 2016
Occurred Source:
http://ir.cidara.com/phoenix.zhtml?c=253962&p=RssLanding&cat=news&id=2176474
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fungal Infections, Cd101 Iv, Cu101 Iv, Candidemia, Invasive Candidiasis, Orphan Drug Designation, Mad Clinical Trial, Echinocandins
